INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 103 filers reported holding INFINITY PHARMACEUTICALS INC in Q3 2013. The put-call ratio across all filers is 0.80 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $2,220,000 | -31.2% | 1,644,813 | -20.5% | 0.00% | -100.0% |
Q3 2016 | $3,226,000 | +23.7% | 2,067,943 | +5.5% | 0.00% | 0.0% |
Q2 2016 | $2,607,000 | -81.8% | 1,960,489 | -28.0% | 0.00% | -66.7% |
Q1 2016 | $14,355,000 | -33.4% | 2,723,919 | -0.8% | 0.00% | -40.0% |
Q4 2015 | $21,559,000 | -8.7% | 2,746,337 | -1.7% | 0.01% | -16.7% |
Q3 2015 | $23,607,000 | -23.3% | 2,793,768 | -0.7% | 0.01% | -14.3% |
Q2 2015 | $30,796,000 | -14.7% | 2,812,412 | +8.9% | 0.01% | -22.2% |
Q1 2015 | $36,100,000 | -12.6% | 2,582,262 | +5.6% | 0.01% | -10.0% |
Q4 2014 | $41,289,000 | +43.1% | 2,444,554 | +13.7% | 0.01% | +25.0% |
Q3 2014 | $28,851,000 | +0.1% | 2,149,839 | -4.9% | 0.01% | 0.0% |
Q2 2014 | $28,813,000 | +27.5% | 2,261,583 | +19.0% | 0.01% | +14.3% |
Q1 2014 | $22,604,000 | -20.1% | 1,901,092 | -7.2% | 0.01% | -22.2% |
Q4 2013 | $28,298,000 | -18.0% | 2,049,092 | +3.5% | 0.01% | -25.0% |
Q3 2013 | $34,495,000 | +18.8% | 1,979,074 | +10.4% | 0.01% | +9.1% |
Q2 2013 | $29,025,000 | – | 1,792,581 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,354,963 | $38,132,000 | 1.80% |
Orbimed Advisors | 4,520,800 | $73,201,000 | 1.55% |
QVT Financial LP | 1,326,610 | $21,480,000 | 1.44% |
BB BIOTECH AG | 1,089,828 | $17,646,000 | 1.27% |
Meditor Group Ltd | 250,000 | $4,048,000 | 0.55% |
Perimeter Capital Partners, LLC | 159,915 | $2,589,000 | 0.50% |
EMERALD MUTUAL FUND ADVISERS TRUST | 156,808 | $2,539,000 | 0.43% |
Broadfin Capital, LLC | 117,172 | $1,897,000 | 0.37% |
OXFORD ASSET MANAGEMENT LLP | 811,331 | $13,184,000 | 0.36% |
Baker Brothers Advisors | 1,016,433 | $16,458,000 | 0.33% |